FR2849029B1 - Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. - Google Patents
Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.Info
- Publication number
- FR2849029B1 FR2849029B1 FR0216412A FR0216412A FR2849029B1 FR 2849029 B1 FR2849029 B1 FR 2849029B1 FR 0216412 A FR0216412 A FR 0216412A FR 0216412 A FR0216412 A FR 0216412A FR 2849029 B1 FR2849029 B1 FR 2849029B1
- Authority
- FR
- France
- Prior art keywords
- enantiomer
- ray diffraction
- diffraction pattern
- interplanar spacings
- maxima corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960001165 modafinil Drugs 0.000 title abstract 2
- 230000003287 optical effect Effects 0.000 title 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 9
- 239000012453 solvate Substances 0.000 abstract 6
- 238000002441 X-ray diffraction Methods 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 230000001777 nootropic effect Effects 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (57)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216412A FR2849029B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
CN200910152177A CN101654423A (zh) | 2002-12-20 | 2003-12-18 | 莫达非尼旋光对映异构体的晶形及其制备方法 |
EP13177648.6A EP2679576A3 (fr) | 2002-12-20 | 2003-12-18 | Procédé de préparation de formes cristallines des énantiomeres optiques du modafinil et leur composition pharmaceutique |
ES03799631.1T ES2627808T3 (es) | 2002-12-20 | 2003-12-18 | Método para la producción de formas cristalinas y formas cristalinas de Enantiomeros ópticos de modafinil |
CA2510096A CA2510096C (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
CA2724305A CA2724305A1 (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
PCT/FR2003/003799 WO2004060858A1 (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
PL377196A PL377196A1 (pl) | 2002-12-20 | 2003-12-18 | Sposób przygotowania i postacie krystaliczne enancjomerów optycznych modafinilu |
MXPA05006525A MXPA05006525A (es) | 2002-12-20 | 2003-12-18 | Procedimiento de preparacion de formas cristalinas de enantiomeros opticos de modafinil. |
UAA200507106A UA100964C2 (ru) | 2002-12-20 | 2003-12-18 | Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила |
CN2010101503175A CN101914044A (zh) | 2002-12-20 | 2003-12-18 | 莫达非尼旋光对映异构体的晶形及其制备方法 |
KR1020057011619A KR101050565B1 (ko) | 2002-12-20 | 2003-12-18 | 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법 |
SI200332281T SI2343275T1 (sl) | 2002-12-20 | 2003-12-18 | Kristaliniäśna oblika optiäśnih enantiomerov modafinila |
EP13177660.1A EP2679578B1 (fr) | 2002-12-20 | 2003-12-18 | Procédé de préparation et une forme cristalline des énantiomères optiques du modafinil |
NZ540733A NZ540733A (en) | 2002-12-20 | 2003-12-18 | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
EP11163602.3A EP2343275B1 (fr) | 2002-12-20 | 2003-12-18 | Forme cristalline des énantiomères optiques du modafinil. |
DK11163602.3T DK2343275T3 (da) | 2002-12-20 | 2003-12-18 | Krystallinsk form af optiske enantiomerer af modafinil |
EP13177658.5A EP2679577A3 (fr) | 2002-12-20 | 2003-12-18 | Procédé de préparation de formes cristallines des énantiomeres optiques du modafinil et leur composition pharmaceutique |
EP13177661.9A EP2676952A3 (fr) | 2002-12-20 | 2003-12-18 | Procédé de préparation et formes cristallines IV des énantiomères optiques du modafinil |
ES11163602T ES2425023T3 (es) | 2002-12-20 | 2003-12-18 | Forma cristalina de los enantiómeros ópticos de modafinilo |
JP2004564285A JP4719471B2 (ja) | 2002-12-20 | 2003-12-18 | モダフィニルの光学異性体の調製方法及び結晶形 |
AU2003299349A AU2003299349C1 (en) | 2002-12-20 | 2003-12-18 | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
EA200501016A EA009592B1 (ru) | 2002-12-20 | 2003-12-18 | Способ получения кристаллических форм и кристаллические формы оптических энантиомеров модафинила |
PT111636023T PT2343275E (pt) | 2002-12-20 | 2003-12-18 | Forma cristalina dos enantiómeros ópticos de modafinil |
BRPI0316916-2A BRPI0316916B1 (pt) | 2002-12-20 | 2003-12-18 | Processo para a preparação de formas cristalinas polimórficas de enantiômeros óticos levógiro de modafinila |
US10/539,918 US7132570B2 (en) | 2002-12-20 | 2003-12-18 | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
NZ571235A NZ571235A (en) | 2002-12-20 | 2003-12-18 | Process for the preparation of optically active 2-benzhydrylsulfinylacetamide |
ES13177660.1T ES2575018T3 (es) | 2002-12-20 | 2003-12-18 | Forma cristalina de los enantiómeros ópticos de modafinilo |
CNB2003801098134A CN100540533C (zh) | 2002-12-20 | 2003-12-18 | 莫达非尼旋光对映异构体的晶形及其制备方法 |
CN201610461501.9A CN106065007A (zh) | 2002-12-20 | 2003-12-18 | 莫达非尼旋光对映异构体的晶形及其制备方法 |
CN2007100017638A CN101012189B (zh) | 2002-12-20 | 2003-12-18 | 莫达非尼旋光对映异构体的晶形及其制备方法 |
EP03799631.1A EP1572635B1 (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
ARP030104730A AR042546A1 (es) | 2002-12-20 | 2003-12-19 | Procedimiento de preparacion y formas cristalinas de los enantiomeros de modafinil, composiciones farmaceuticas y medicamentos que los contienen |
TW092136443A TWI344952B (en) | 2002-12-20 | 2003-12-22 | Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
MYPI20034935A MY142926A (en) | 2002-12-20 | 2003-12-22 | Method of the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
ZA200504805A ZA200504805B (en) | 2002-12-20 | 2005-06-13 | Method for the procution of crystalline forms and crystalline forms of optical enantiomers of modafinil |
NO20052912A NO335724B1 (no) | 2002-12-20 | 2005-06-15 | Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse |
IL169205A IL169205A (en) | 2002-12-20 | 2005-06-16 | Polymorphically modulating abortifacient enantiomer, (i) form (i) of (-) - modafinil, pharmaceutical preparation and process for the preparation of (-) form (i) - modafinil polymorph |
EGNA2005000326 EG24849A (en) | 2002-12-20 | 2005-06-19 | Method for the production of crystalline forms andcrystalline forms of optical enantiomers of modaf inil |
IS7947A IS7947A (is) | 2002-12-20 | 2005-07-19 | Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafíníls |
HK11112662.9A HK1158171A1 (en) | 2002-12-20 | 2005-12-15 | Crystalline form of the optical enantiomers of modafinil |
US11/474,859 US20060241320A1 (en) | 2002-12-20 | 2006-06-26 | Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
CL2007002450A CL2007002450A1 (es) | 2002-12-20 | 2007-08-22 | Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03). |
US12/507,594 US20090281192A1 (en) | 2002-12-20 | 2009-07-22 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
US12/507,610 US20100048719A1 (en) | 2002-12-20 | 2009-07-22 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
US12/507,602 US20100048718A1 (en) | 2002-12-20 | 2009-07-22 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
US12/507,584 US9382200B2 (en) | 2002-12-20 | 2009-07-22 | Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
US12/507,631 US20100048720A1 (en) | 2002-12-20 | 2009-07-22 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
US12/507,623 US20090281193A1 (en) | 2002-12-20 | 2009-07-22 | Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
AU2010212462A AU2010212462A1 (en) | 2002-12-20 | 2010-08-20 | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
JP2011032155A JP5497680B2 (ja) | 2002-12-20 | 2011-02-17 | モダフィニルの異性体の調製方法及び結晶形 |
US13/858,483 US8729305B2 (en) | 2002-12-20 | 2013-04-08 | Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
CY20131100573T CY1114291T1 (el) | 2002-12-20 | 2013-07-08 | Κρυσταλλικη μορφη των οπτικων εναντιομερων της μοδαφινιλης |
US14/012,363 US8975442B2 (en) | 2002-12-20 | 2013-08-28 | Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
HK14105599.8A HK1192222A1 (zh) | 2002-12-20 | 2014-06-13 | 莫達非尼光學對映異構體的晶形及其製備方法 |
CL2016002640A CL2016002640A1 (es) | 2002-12-20 | 2016-10-17 | Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003). |
HK16113750A HK1225371A1 (zh) | 2002-12-20 | 2016-12-01 | 莫達非尼旋光對映異構體的晶形及其製備方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216412A FR2849029B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2849029A1 FR2849029A1 (fr) | 2004-06-25 |
FR2849029B1 true FR2849029B1 (fr) | 2005-03-18 |
Family
ID=32406320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0216412A Expired - Fee Related FR2849029B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
Country Status (29)
Country | Link |
---|---|
US (10) | US7132570B2 (no) |
EP (6) | EP2679577A3 (no) |
JP (2) | JP4719471B2 (no) |
KR (1) | KR101050565B1 (no) |
CN (5) | CN101914044A (no) |
AR (1) | AR042546A1 (no) |
AU (2) | AU2003299349C1 (no) |
CA (2) | CA2510096C (no) |
CL (2) | CL2007002450A1 (no) |
CY (1) | CY1114291T1 (no) |
DK (1) | DK2343275T3 (no) |
EA (1) | EA009592B1 (no) |
EG (1) | EG24849A (no) |
ES (3) | ES2627808T3 (no) |
FR (1) | FR2849029B1 (no) |
HK (2) | HK1192222A1 (no) |
IL (1) | IL169205A (no) |
IS (1) | IS7947A (no) |
MX (1) | MXPA05006525A (no) |
MY (1) | MY142926A (no) |
NO (1) | NO335724B1 (no) |
NZ (2) | NZ540733A (no) |
PL (1) | PL377196A1 (no) |
PT (1) | PT2343275E (no) |
SI (1) | SI2343275T1 (no) |
TW (1) | TWI344952B (no) |
UA (1) | UA100964C2 (no) |
WO (1) | WO2004060858A1 (no) |
ZA (1) | ZA200504805B (no) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050025791A1 (en) | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
JP4906233B2 (ja) | 2002-03-01 | 2012-03-28 | ユニバーシティー オブ サウス フロリダ | 少なくとも1種の有効薬剤成分を含有する多構成要素固相 |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
AU2003217437A1 (en) * | 2003-03-17 | 2004-10-11 | Hetero Drugs Limited | Novel crystalline forms of lamotrigine |
ES2487415T3 (es) * | 2003-03-17 | 2014-08-20 | Neurohealing Pharmaceuticals, Inc. | Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales |
EP1670753A4 (en) * | 2003-09-04 | 2008-01-02 | Cephalon Inc | MODAFINIL COMPOSITIONS |
EP1516869A1 (en) | 2003-09-19 | 2005-03-23 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
EP2292213A1 (en) * | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
EA009949B1 (ru) * | 2004-02-06 | 2008-04-28 | Сефалон, Инк. | Композиции модафинила |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
US20060086667A1 (en) * | 2004-09-13 | 2006-04-27 | Cephalon, Inc., U.S. Corporation | Methods for the separation of enantiomeric sulfinylacetamides |
EP1702915A1 (en) | 2005-03-14 | 2006-09-20 | Cephalon France | Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation |
EP1909573A4 (en) * | 2005-07-21 | 2010-09-22 | Neurohealing Pharmaceuticals I | SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE |
EP1986994A2 (en) * | 2006-02-21 | 2008-11-05 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of armodafinil and preparation thereof |
CA2634133A1 (en) | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | An improved process for the preparation of armodafinil |
CA2657409A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Corporation, Plc | Nanoparticulate formulations of modafinil |
DK2056811T3 (en) * | 2006-08-14 | 2018-05-22 | Neurohealing Pharmaceuticals Inc | Modafinil-based treatment for premature ejaculation |
US20080214862A1 (en) * | 2006-12-06 | 2008-09-04 | Ben-Zion Dolitzky | Processes for preparing armodafinil intermediate |
CN101641090B (zh) * | 2006-12-19 | 2012-12-05 | 亚勒斯有限公司 | 莫达非尼在制备治疗多动腿综合征的药物中的应用 |
CA2688430A1 (en) * | 2007-06-04 | 2008-12-11 | Generics [Uk] Limited | Novel process |
WO2009024863A2 (en) * | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
US7960586B2 (en) * | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
US20090082462A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched armodafinil |
US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
WO2009090663A1 (en) * | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
US20100036164A1 (en) * | 2008-08-06 | 2010-02-11 | Srinivas Areveli | Preparation of armodafinil form i |
EP2292306B1 (en) * | 2009-09-02 | 2013-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device |
EP2501674A2 (en) * | 2009-11-19 | 2012-09-26 | Ranbaxy Laboratories Limited | Processes for preparation of polymorphic forms of lacosamide |
CA2786026A1 (en) * | 2010-01-07 | 2011-07-14 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
US9267159B2 (en) | 2010-12-08 | 2016-02-23 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation | シクロデキストリンとの混合体を含有する錠剤 |
US10466776B2 (en) * | 2014-06-24 | 2019-11-05 | Paypal, Inc. | Surfacing related content based on user interaction with currently presented content |
US10609267B2 (en) * | 2014-07-23 | 2020-03-31 | Orcam Technologies Ltd. | Systems and methods for analyzing advertisement effectiveness using wearable camera systems |
CN107000038A (zh) * | 2014-11-27 | 2017-08-01 | 株式会社Gc | 蜡模的表面处理剂以及制造牙科假体的方法 |
WO2017064723A1 (en) * | 2015-10-12 | 2017-04-20 | Natco Pharma Ltd | An improved process for the preparation of armodafinil |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1905990A (en) | 1931-01-02 | 1933-04-25 | Hoffmann La Roche | Disubstituted carbamic acid esters of phenols containing a basic constituent |
GB1197809A (en) | 1968-02-13 | 1970-07-08 | Inst Noguchi | Method for Continuous Optical Resolution of Organic Racemates. |
GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
FR2593809B1 (fr) | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
FR2597864B1 (fr) | 1986-04-28 | 1990-11-16 | Lafon Labor | Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique |
FR2626881B1 (fr) | 1988-02-10 | 1990-07-27 | Lafon Labor | 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique |
FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
FR2671349B1 (fr) | 1991-01-09 | 1993-04-23 | Lafon Labor | Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant. |
FR2710337B1 (fr) * | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
CN1249932A (zh) | 1999-09-29 | 2000-04-12 | 付俊昌 | 一种莫达芬尼及其光学对映体l及d异构体的新用途 |
CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US20010036640A1 (en) | 2000-04-25 | 2001-11-01 | D'amico Kevin L. | System and methods for the high throughput screening of polymorphs |
US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
DE10025756C2 (de) * | 2000-05-25 | 2003-02-20 | Cognis Deutschland Gmbh | Lösungsvermittler |
JP4302977B2 (ja) * | 2000-07-27 | 2009-07-29 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶性の且つ純粋なモダフィニルおよびそれを製造する方法 |
US6835307B2 (en) * | 2000-08-04 | 2004-12-28 | Battelle Memorial Institute | Thermal water treatment |
US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
EP1332130A4 (en) | 2000-11-03 | 2004-01-21 | Teva Pharma | HEMICALCIC ATORVASTATIN FORM VII |
KR100911779B1 (ko) * | 2001-05-25 | 2009-08-12 | 세파론, 인코포레이티드 | 모다피닐을 포함하는 고형 제약 제제 |
US20030118078A1 (en) | 2001-08-10 | 2003-06-26 | Carlson Eric D. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
US7702071B2 (en) | 2002-01-15 | 2010-04-20 | Avantium International B.V. | Method for performing power diffraction analysis |
US6875893B2 (en) * | 2002-05-23 | 2005-04-05 | Cephalon, Inc. | Preparations of a sulfinyl acetamide |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
CA2491908C (en) | 2002-08-02 | 2011-09-13 | Avantium International B.V. | An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments |
US6992219B2 (en) | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
EP1567497B1 (en) | 2002-12-06 | 2009-09-23 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
CA2534664C (en) | 2003-09-04 | 2012-10-30 | Cephalon, Inc. | Modafinil compositions |
EA009949B1 (ru) | 2004-02-06 | 2008-04-28 | Сефалон, Инк. | Композиции модафинила |
US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
EP2708531A1 (en) | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
EP1909573A4 (en) * | 2005-07-21 | 2010-09-22 | Neurohealing Pharmaceuticals I | SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE |
EP1986994A2 (en) | 2006-02-21 | 2008-11-05 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of armodafinil and preparation thereof |
CA2634133A1 (en) | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | An improved process for the preparation of armodafinil |
CA2688430A1 (en) | 2007-06-04 | 2008-12-11 | Generics [Uk] Limited | Novel process |
WO2009024863A2 (en) | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
US7960586B2 (en) | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
EP1911739A3 (en) * | 2007-11-05 | 2008-09-17 | Dipharma Francis S.r.l. | Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate |
WO2009090663A1 (en) | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
-
2002
- 2002-12-20 FR FR0216412A patent/FR2849029B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-18 US US10/539,918 patent/US7132570B2/en not_active Expired - Fee Related
- 2003-12-18 ES ES03799631.1T patent/ES2627808T3/es not_active Expired - Lifetime
- 2003-12-18 EP EP13177658.5A patent/EP2679577A3/fr not_active Withdrawn
- 2003-12-18 AU AU2003299349A patent/AU2003299349C1/en active Active
- 2003-12-18 NZ NZ540733A patent/NZ540733A/en not_active IP Right Cessation
- 2003-12-18 EP EP13177661.9A patent/EP2676952A3/fr not_active Withdrawn
- 2003-12-18 ES ES13177660.1T patent/ES2575018T3/es not_active Expired - Lifetime
- 2003-12-18 WO PCT/FR2003/003799 patent/WO2004060858A1/fr active Application Filing
- 2003-12-18 KR KR1020057011619A patent/KR101050565B1/ko active IP Right Grant
- 2003-12-18 CN CN2010101503175A patent/CN101914044A/zh active Pending
- 2003-12-18 PT PT111636023T patent/PT2343275E/pt unknown
- 2003-12-18 EP EP13177660.1A patent/EP2679578B1/fr not_active Expired - Lifetime
- 2003-12-18 EP EP13177648.6A patent/EP2679576A3/fr not_active Withdrawn
- 2003-12-18 DK DK11163602.3T patent/DK2343275T3/da active
- 2003-12-18 NZ NZ571235A patent/NZ571235A/en not_active IP Right Cessation
- 2003-12-18 JP JP2004564285A patent/JP4719471B2/ja not_active Expired - Fee Related
- 2003-12-18 CN CNB2003801098134A patent/CN100540533C/zh not_active Expired - Fee Related
- 2003-12-18 UA UAA200507106A patent/UA100964C2/ru unknown
- 2003-12-18 CN CN2007100017638A patent/CN101012189B/zh not_active Expired - Fee Related
- 2003-12-18 CN CN201610461501.9A patent/CN106065007A/zh active Pending
- 2003-12-18 SI SI200332281T patent/SI2343275T1/sl unknown
- 2003-12-18 PL PL377196A patent/PL377196A1/pl unknown
- 2003-12-18 ES ES11163602T patent/ES2425023T3/es not_active Expired - Lifetime
- 2003-12-18 EP EP03799631.1A patent/EP1572635B1/fr not_active Expired - Lifetime
- 2003-12-18 CA CA2510096A patent/CA2510096C/fr not_active Expired - Lifetime
- 2003-12-18 CN CN200910152177A patent/CN101654423A/zh active Pending
- 2003-12-18 EA EA200501016A patent/EA009592B1/ru not_active IP Right Cessation
- 2003-12-18 MX MXPA05006525A patent/MXPA05006525A/es active IP Right Grant
- 2003-12-18 EP EP11163602.3A patent/EP2343275B1/fr not_active Expired - Lifetime
- 2003-12-18 CA CA2724305A patent/CA2724305A1/fr not_active Abandoned
- 2003-12-19 AR ARP030104730A patent/AR042546A1/es not_active Application Discontinuation
- 2003-12-22 MY MYPI20034935A patent/MY142926A/en unknown
- 2003-12-22 TW TW092136443A patent/TWI344952B/zh not_active IP Right Cessation
-
2005
- 2005-06-13 ZA ZA200504805A patent/ZA200504805B/en unknown
- 2005-06-15 NO NO20052912A patent/NO335724B1/no not_active IP Right Cessation
- 2005-06-16 IL IL169205A patent/IL169205A/en active IP Right Grant
- 2005-06-19 EG EGNA2005000326 patent/EG24849A/xx active
- 2005-07-19 IS IS7947A patent/IS7947A/is unknown
-
2006
- 2006-06-26 US US11/474,859 patent/US20060241320A1/en not_active Abandoned
-
2007
- 2007-08-22 CL CL2007002450A patent/CL2007002450A1/es unknown
-
2009
- 2009-07-22 US US12/507,631 patent/US20100048720A1/en not_active Abandoned
- 2009-07-22 US US12/507,623 patent/US20090281193A1/en not_active Abandoned
- 2009-07-22 US US12/507,584 patent/US9382200B2/en not_active Expired - Fee Related
- 2009-07-22 US US12/507,594 patent/US20090281192A1/en not_active Abandoned
- 2009-07-22 US US12/507,610 patent/US20100048719A1/en not_active Abandoned
- 2009-07-22 US US12/507,602 patent/US20100048718A1/en not_active Abandoned
-
2010
- 2010-08-20 AU AU2010212462A patent/AU2010212462A1/en not_active Abandoned
-
2011
- 2011-02-17 JP JP2011032155A patent/JP5497680B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-08 US US13/858,483 patent/US8729305B2/en not_active Expired - Fee Related
- 2013-07-08 CY CY20131100573T patent/CY1114291T1/el unknown
- 2013-08-28 US US14/012,363 patent/US8975442B2/en not_active Expired - Fee Related
-
2014
- 2014-06-13 HK HK14105599.8A patent/HK1192222A1/zh not_active IP Right Cessation
-
2016
- 2016-10-17 CL CL2016002640A patent/CL2016002640A1/es unknown
- 2016-12-01 HK HK16113750A patent/HK1225371A1/zh unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US8492423B2 (en) | 2002-12-30 | 2013-07-23 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2849029B1 (fr) | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. | |
ES2307209T3 (es) | Procedimiento de produccion de un enantiomero de amlodipina con una pureza optica alta. | |
DE60311599T2 (de) | Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten | |
SE0103046D0 (sv) | Kristallin bas av citalopram | |
PT100673B (pt) | Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos | |
JP5503546B2 (ja) | 4,5−ジメトキシ−1−(メチルアミノメチル)−ベンゾシクロブタンの分離 | |
KR100459149B1 (ko) | 트레오-메틸페니데이트의분리방법 | |
PT768309E (pt) | Processo para a preparacao de compostos de imidazolilo enantiomericamente puros | |
BR0109507A (pt) | Processo para preparação de forma i, cristalina, de carbegolina | |
RU97100948A (ru) | Способ расщепления рацематов трамадола | |
KR970059155A (ko) | 트라마돌의 라세미체를 분리하는 방법 | |
WO2001083422A1 (en) | Process for the separation of the cis trans diastereoisomers of tramadol | |
AR030938A1 (es) | Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso | |
KR102236806B1 (ko) | 거울상 이성질체 농후화된 3-아미노피페리딘의 제조 방법 | |
AR032433A1 (es) | Proceso para la preparacion de un isomero de anillo de 5 miembros 3-sustituido y compuestos intermediarios utiles en el mismo | |
BRPI0719205A2 (pt) | Processo para a preparação de pleuromutilins | |
ATE407933T1 (de) | Verfahren zur herstellung von paroxetin hydrochlorid hemihydrat | |
ATE402157T1 (de) | Verfahren zur herstellung von mycophenolatmofetil | |
AR012346A1 (es) | Proceso para la fabricacion de compuestos racemicos, compuestos obtenidos por dicho proceso y compuestos intermediarios | |
KR20190128663A (ko) | 라세믹 3-알킬피페리딘-카르복실산 에틸 에스테르의 광학 이성질체를 분리하는 방법 | |
BRPI0621138A2 (pt) | processo para a preparação de s-(+)-clopidogrel | |
KR20010006117A (ko) | 단일 에난티오머 나웨딘을 제조하기 위한 방법 | |
KR20170048878A (ko) | 시탈로프람 및 에스시탈로프람의 신규 제조방법 | |
DE60219837D1 (de) | Kristalline form von quinapril hydrochlorid und verfahren zu dessen herstellung | |
KR20090023603A (ko) | 네포팜과 유사체의 거울상 이성질체의 라세미화 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CA | Change of address | ||
CD | Change of name or company name | ||
CJ | Change in legal form | ||
TP | Transmission of property | ||
TP | Transmission of property |
Owner name: TEVA SANTE, FR Effective date: 20140306 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
ST | Notification of lapse |
Effective date: 20180831 |